BR112022001324A2 - Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo - Google Patents
Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmoInfo
- Publication number
- BR112022001324A2 BR112022001324A2 BR112022001324A BR112022001324A BR112022001324A2 BR 112022001324 A2 BR112022001324 A2 BR 112022001324A2 BR 112022001324 A BR112022001324 A BR 112022001324A BR 112022001324 A BR112022001324 A BR 112022001324A BR 112022001324 A2 BR112022001324 A2 BR 112022001324A2
- Authority
- BR
- Brazil
- Prior art keywords
- map kinase
- treating
- subject
- compound
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962881026P | 2019-07-31 | 2019-07-31 | |
| PCT/US2020/044558 WO2021022186A1 (en) | 2019-07-31 | 2020-07-31 | Deuterated mk2 pathway inhibitors and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022001324A2 true BR112022001324A2 (pt) | 2022-03-22 |
Family
ID=74228512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022001324A BR112022001324A2 (pt) | 2019-07-31 | 2020-07-31 | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12403141B2 (https=) |
| EP (1) | EP4003344A4 (https=) |
| JP (1) | JP2022542434A (https=) |
| KR (1) | KR20220041180A (https=) |
| CN (1) | CN114206339A (https=) |
| AU (1) | AU2020319879A1 (https=) |
| BR (1) | BR112022001324A2 (https=) |
| CA (1) | CA3149304A1 (https=) |
| IL (1) | IL290045A (https=) |
| MX (1) | MX2022001151A (https=) |
| PH (1) | PH12022550029A1 (https=) |
| WO (1) | WO2021022186A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220161396A (ko) * | 2020-03-27 | 2022-12-06 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 치환된 피리디논-피리디닐 화합물의 제조, 조성물, 및 결정형 |
| BR112023019861A2 (pt) | 2021-03-31 | 2023-11-07 | Xinthera Inc | Inibidores de mk2 e usos dos mesmos |
| EP4367099A4 (en) | 2021-07-09 | 2025-06-04 | Xinthera, Inc. | Pyridinone mk2 inhibitors and uses thereof |
| WO2023001282A1 (zh) * | 2021-07-23 | 2023-01-26 | 南京明德新药研发有限公司 | 杂环取代的嘧啶衍生物 |
| CN116444492B (zh) * | 2021-12-29 | 2026-03-03 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| CN116396274B (zh) * | 2022-01-06 | 2025-11-11 | 深圳信立泰药业股份有限公司 | 一种取代的联吡啶酮类化合物及其制备方法与应用 |
| EP4464694A4 (en) | 2022-01-14 | 2026-04-01 | Shanghai Hansoh Biomedical Co Ltd | POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE |
| CN116444493A (zh) * | 2022-01-14 | 2023-07-18 | 上海翰森生物医药科技有限公司 | 含双并环类衍生物、其制备方法和应用 |
| WO2023150709A2 (en) * | 2022-02-04 | 2023-08-10 | Aclaris Therapeutics, Inc. | Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds |
| CN119384410A (zh) * | 2022-03-03 | 2025-01-28 | 深圳信立泰药业股份有限公司 | 一种氘代三联吡啶二酮化合物或其盐及其制备方法与应用 |
| EP4650347A1 (en) * | 2023-01-13 | 2025-11-19 | Shanghai Meiyue Biotech Development Co., Ltd. | Phenyl-substituted heteroaryl compound and pharmaceutical composition comprising same, preparation method therefor and use thereof |
| JP2026504073A (ja) * | 2023-01-13 | 2026-02-03 | プールベグ ファーマ（ユーケー） リミテッド | がん免疫療法関連サイトカイン放出症候群の軽減のための医薬品および方法 |
| WO2025093869A1 (en) * | 2023-11-01 | 2025-05-08 | Poolbeg Pharma (UK) Limited | P38 map kinase inhibitor for use in the treatment of inflammation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008141057A1 (en) * | 2007-05-08 | 2008-11-20 | Auspex Pharmaceuticals, Inc. | Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea |
| JP5466759B2 (ja) * | 2009-05-28 | 2014-04-09 | ノバルティス アーゲー | ネプリライシン阻害剤としての置換アミノ酪酸誘導体 |
| US8575348B2 (en) * | 2009-07-28 | 2013-11-05 | Auspex Pharmaceuticals, Inc | Quinolone inhibitors of lipoprotein-associated phospholipase A2 |
| US9359300B2 (en) * | 2010-12-06 | 2016-06-07 | Confluence Life Sciences, Inc. | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
| SI2648516T1 (sl) * | 2010-12-06 | 2019-01-31 | Aclaris Therapeutics, Inc. | Substituirane spojine piridinon-piridinila |
| HUE054178T2 (hu) * | 2013-06-07 | 2021-08-30 | Aclaris Therapeutics Inc | Metil/fluor-piridinil-metoxi-szubsztituált piridinon-piridinil-vegyületek és fluor-pirimidinil-metoxi-szubsztituált piridinon-piridinil-vegyületek |
| CZ2015601A3 (cs) * | 2015-09-02 | 2017-03-15 | Zentiva, K.S. | Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty |
| EP3442940A1 (en) * | 2016-04-11 | 2019-02-20 | Clexio Biosciences Ltd. | Deuterated ketamine derivatives |
| WO2018229683A1 (en) * | 2017-06-15 | 2018-12-20 | Novartis Ag | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
| EP3720436A4 (en) | 2017-12-06 | 2021-06-02 | Lin Bioscience, Pty Ltd. | TUBULIN INHIBITORS |
| US20230087078A1 (en) | 2020-03-02 | 2023-03-23 | Washington University | Compositions and methods for the treatment of pancreatic cancer |
-
2020
- 2020-07-31 JP JP2022506384A patent/JP2022542434A/ja not_active Ceased
- 2020-07-31 WO PCT/US2020/044558 patent/WO2021022186A1/en not_active Ceased
- 2020-07-31 PH PH1/2022/550029A patent/PH12022550029A1/en unknown
- 2020-07-31 BR BR112022001324A patent/BR112022001324A2/pt not_active IP Right Cessation
- 2020-07-31 CA CA3149304A patent/CA3149304A1/en active Pending
- 2020-07-31 EP EP20847487.4A patent/EP4003344A4/en active Pending
- 2020-07-31 CN CN202080051376.9A patent/CN114206339A/zh active Pending
- 2020-07-31 MX MX2022001151A patent/MX2022001151A/es unknown
- 2020-07-31 AU AU2020319879A patent/AU2020319879A1/en not_active Abandoned
- 2020-07-31 US US17/630,414 patent/US12403141B2/en active Active
- 2020-07-31 KR KR1020227006713A patent/KR20220041180A/ko active Pending
-
2022
- 2022-01-23 IL IL290045A patent/IL290045A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL290045A (en) | 2022-03-01 |
| WO2021022186A1 (en) | 2021-02-04 |
| CA3149304A1 (en) | 2021-02-04 |
| MX2022001151A (es) | 2022-02-22 |
| CN114206339A (zh) | 2022-03-18 |
| JP2022542434A (ja) | 2022-10-03 |
| KR20220041180A (ko) | 2022-03-31 |
| EP4003344A4 (en) | 2023-07-26 |
| PH12022550029A1 (en) | 2023-02-27 |
| US20220288070A1 (en) | 2022-09-15 |
| US12403141B2 (en) | 2025-09-02 |
| AU2020319879A1 (en) | 2022-02-03 |
| EP4003344A1 (en) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| CO2022018811A2 (es) | Inhibidores de la proteína kras g12c y usos de estos | |
| BR112021024674A2 (pt) | Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| BR112022010112A2 (pt) | Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica | |
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| BR112019012217A2 (pt) | compostos de amino-triazolopiridina e seu uso no tratamento de câncer | |
| ECSP19030002A (es) | 1,2,4-triazolonas 2,4,5-trisustituidas | |
| BR112017026159A2 (pt) | inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer | |
| BR112018071093A2 (pt) | composto de fórmula, composição farmacêutica, e método para prevenir ou tratar um distúrbio sanguíneo | |
| BRPI0818533B8 (pt) | composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
| BR112012006686B8 (pt) | compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa | |
| BRPI0910439B8 (pt) | derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos | |
| BRPI0910832B8 (pt) | derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos. | |
| BR112019001253A2 (pt) | composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson. | |
| BR112019024264A2 (pt) | Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer | |
| BR112012028445A2 (pt) | compostos de heteroarila bicíclica como moduladores de gpr119 | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
| BR112022001567A2 (pt) | Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias. | |
| BRPI0905687A8 (pt) | composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto | |
| BR112022015792A2 (pt) | Inibidores de pad4 heterocíclicos | |
| BR112016030730A8 (pt) | composto | |
| BRPI0513858B8 (pt) | compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2841 DE 17-06-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |